Drug Trial Radar · NCT02752776
A Study to Evaluate Clear Skin Effect on Quality of Life in Patients With Plaque Psoriasis.
Last checked: Nov 20, 2026Latest source record: Sep 25, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,660
Actual
Start
Mar 17, 2016
Primary completion
Mar 28, 2018
Study completion Mar 28, 2018
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Apr 27, 2016
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Other
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Study of effects of secukinumab 300 mg s.c. on quality of life (QoL) in psoriasis in patients with or without prior exposure to systemic therapy.
Conditions
- Plaque Psoriasis
Interventions
SecukinumabDrug
Secukinumab was used as commercially available PFS of 150 mg. Patients received PFS at the site and were instructed to administer Secukinumab as needed (300 mg each application).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With a Dermatology Life Quality Index 0/1 (DLQI 0/1) Response at Week 16Time frame: 16 weeks
Locations
215 sites in 17 countries. Site status is shown where the registry gives one.
Novartis Investigative Site
Bruges, Belgium
Novartis Investigative Site
Ghent, Belgium
Novartis Investigative Site
Seraing, Belgium
Novartis Investigative Site
Geel, BEL, Belgium
Novartis Investigative Site
Pleven, Bulgaria
Novartis Investigative Site
Sofia, Bulgaria
Novartis Investigative Site
Sofia, Bulgaria
Novartis Investigative Site
Stara Zagora, Bulgaria
Novartis Investigative Site
Varna, Bulgaria
Novartis Investigative Site
Pilsen, Czechia
Novartis Investigative Site
Prague, Czechia
Novartis Investigative Site
Prague, Czechia
Novartis Investigative Site
Ústí nad Labem, Czech Republic, Czechia
Novartis Investigative Site
Tallinn, Estonia
Novartis Investigative Site
Tallinn, Estonia
Novartis Investigative Site
Tartu, Estonia
Novartis Investigative Site
Angers, France
Novartis Investigative Site
Antony, France
Novartis Investigative Site
Argenteuil, France
Novartis Investigative Site
Auxerre, France
Novartis Investigative Site
Bayonne, France
Novartis Investigative Site
Bordeaux, France
Novartis Investigative Site
Boulogne-sur-Mer, France
Novartis Investigative Site
Brest, France
Novartis Investigative Site
Caen, France
Novartis Investigative Site
Cannes, France
Novartis Investigative Site
Clermont-Ferrand, France
Novartis Investigative Site
Dijon, France
Novartis Investigative Site
Grenoble, France
Novartis Investigative Site
La Rochelle, France
Novartis Investigative Site
Lille, France
Novartis Investigative Site
Marseille, France
Novartis Investigative Site
Martigues, France
Novartis Investigative Site
Montpellier, France
Novartis Investigative Site
Nice, France
Novartis Investigative Site
Nîmes, France
Novartis Investigative Site
Pierre-Bénite, France
Novartis Investigative Site
Pringy, France
Novartis Investigative Site
Quimper, France
Novartis Investigative Site
Reims, France
Showing 40 of 215 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.